Safety and Biotech Investing Don’t Mix

Investors have a fresh reminder of an old truth: Safety is an elusive quality in biotech stocks.

Sage Therapeutics revealed Thursday that its late-stage clinical trial for an experimental treatment for major depressive disorder didn’t succeed. Shares plunged nearly 60% in morning trading, erasing more than $4 billion in market value.